Path ID: DB11750_MESH_D003876_2
Concepts
| Identifier | Name | Type |
|---|---|---|
| MESH:D002990 | Clobetasol | Drug |
| UniProt:P04150 | Glucocorticoid receptor | Protein |
| MESH:D016753 | Interleukin-10 | ChemicalSubstance |
| InterPro:IPR000451 | NF-kappa-B/Dorsal | GeneFamily |
| GO:0006954 | inflammatory response | BiologicalProcess |
| HP:0011123 | Inflammatory abnormality of the skin | PhenotypicFeature |
| MESH:D003876 | Dermatitis, Atopic | Disease |
Relationships
NOTE: predicates are annotated in Biolink Model (v1.3.0)
| Subject | Predicate | Object |
|---|---|---|
| Clobetasol | INCREASES ACTIVITY OF | Glucocorticoid Receptor |
| Glucocorticoid Receptor | INCREASES ACTIVITY OF | Interleukin-10 |
| Interleukin-10 | NEGATIVELY REGULATES | Nf-Kappa-B/Dorsal |
| Nf-Kappa-B/Dorsal | POSITIVELY REGULATES | Inflammatory Response |
| Inflammatory Response | POSITIVELY CORRELATED WITH | Inflammatory Abnormality Of The Skin |
| Inflammatory Abnormality Of The Skin | CONTRIBUTES TO | Dermatitis, Atopic |
Comment: Clobetasol is under investigation for the treatment of Scleroderma. Clobetasol propionate is a propionate ester of clobetasol which act as a glucocorticoid receptor and approved for the treatment of dermatoses.
Reference: